Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2, Double-Blind, Double-Dummy, Placebo-Controlled, Multicenter Study of the Efficacy, Safety, and Tolerability of Vurolenatide in Adult Patients With Short Bowel Syndrome

Next Previous
X
Search
Trial Profile

A Phase 2, Double-Blind, Double-Dummy, Placebo-Controlled, Multicenter Study of the Efficacy, Safety, and Tolerability of Vurolenatide in Adult Patients With Short Bowel Syndrome

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 29 May 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Vurolenatide (Primary)
  • Indications Short bowel syndrome
  • Focus Therapeutic Use
  • Acronyms VIBRANT
  • Sponsors 9 Meters Biopharma [CEASED]

    • Most Recent Events

    • 15 May 2023 According to a 9 Meters Biopharma media release, data from this study were presented at the ASPEN 2023 Nutrition Science & Practice Conference which took place in Las Vegas, Nevada, April 20 - 23.
    • 28 Mar 2023 According to a 9 Meters Biopharma media release, data from this study will be presented at the forthcoming ASPEN 2023 Nutrition Science & Practice Conference.
    • 26 Sep 2022 Status changed from recruiting to completed, according to a 9 Meters Biopharma media release.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top